No Infection Among 56K Vaccinated People
On November 6, the 3rd Hongqiao International Health Technology Innovation Forum was held in the 3rd CIIE Pavilion. At the forum, Liu Jingzhen, Chairman of Sinopharm Group, said when talking about the COVID-19 vaccine related topics, there are currently hundreds of thousands. People were vaccinated urgently with two new inactivated vaccines under the Sinopharm Group. There was no serious adverse reaction. The number of people who left the country after vaccination reached 56,000, and none of them have been infected.
Liu Jingzhen introduced that starting from June this year, Sinopharm’s COVID-19 vaccine has carried out international clinical trials in more than ten countries and regions including the UAE, Bahrain, Egypt, Jordan, Peru, Argentina, and Morocco. So far, the number of vaccinated patients has exceeded 50,000 people.
“The effect of this process is very satisfactory. It has led to the UAE, Bahrain and other countries to announce the emergency use of the two vaccines of Sinopharm.” Liu Jingzhen also said that he was injected with the COVID-19 vaccine in March this year. reaction”.
In July this year, China initiated emergency use of the COVID-19 vaccine. Liu Jingzhen introduced that so far, hundreds of thousands of people have been vaccinated urgently with the COVID-19 vaccine under the Sinopharm Group, and there has not been a single serious adverse reaction. Among them, 56,000 people have left the country after the vaccination. There is currently no case of infection.
According to Liu Jingzhen’s statement, the above-mentioned departing persons involved Chinese petroleum, petrochemical, and electronic technology companies.
Liu Jingzhen said that whether it is from scientific research test data or use around the world, the effectiveness of the COVID-19 vaccine has been proved.
Regarding the future production capacity of vaccines, Liu Jingzhen said that by the end of this year, the production capacity of Sinopharm’s COVID-19 vaccine will probably reach about 100 million doses. According to national requirements, the production capacity will exceed 1 billion doses next year. “It can be used by the Chinese people in particular next year.”